In patients with benign prostate hyperplasia who received tamsulosin 0.2 mg for more than 4 weeks, the improvement of the lower urinary tract symptom terazosin 5 mg administered for 12 weeks
- Conditions
- Diseases of The genitoruinary system
- Registration Number
- KCT0004566
- Lead Sponsor
- Dankook Univeristy Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Male
- Target Recruitment
- 51
1) Male over 40 years
2) Patients diagnosed with benign prostatic hyperplasia
3) Patients have an IPSS score of at least 8
4) Patients who have been prescribed Tamsulosin 0.2mg for more than 4 weeks but have no significant improvement in IPSS score or maximum urinary velocity (Qmax)
5) Patients who voluntarily decided to participate in this study and agreed in writing to the subject consent form
1) Patients with hypersensitivity to a-blocker family drugs.
2) Patients who are taking cholinergic drugs, diuretics, or ß3-antagonists.
3) Patients with urination disorders due to obvious causes other than benign prostatic hyperplasia.
4) Patients with neurogenic bladder disorders.
5) Patients with urinary tract infections (midstream urine culture> 100,000 colonies/mL)
6) Patients with clinically significant circulatory disorders (myocardial infarction, heart failure, angina pectoris, cardiac arrhythmias, pacemaker use, orthostatic hypotension, uncontrolled hypotension)
7) Participants in other interventions within 6 months of screening
8) Patients who are inappropriate to participate in research as judged by other research managers or researchers
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method International Prostate Symptom Score(IPSS) Improvement
- Secondary Outcome Measures
Name Time Method Assessment of improvement in maximum urine velocity(Qmax);IPSS-QoL Improvement Assessment